IDXX News & Events

IDEXX Laboratories announced the expansion of its Fecal Dx antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone, Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. Beginning in late June, Fecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the United States and Canada will automatically include detection of taeniid tapeworm at no additional cost.

IDEXX Laboratories announced that SDMA, a renal biomarker, will be built into Catalyst CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows. Catalyst SDMA Testing Supported by peer-reviewed studies using the IDEXX SDMA Test, SDMA is recognized by the International Renal Interest Society as a key biomarker for evaluating kidney function in pets. Since introducing the IDEXX SDMA Test in 2015, IDEXX has performed approximately 119 million SDMA patient tests globally primarily through its reference laboratories and increasingly on the Catalyst platform, underscoring the test's clinical importance and broad adoption in kidney health evaluation. Results are seamlessly integrated into VetConnect PLUS, alongside other diagnostic data.

FY26 consensus $14.51. Raises FY26 reported revenue growth view to 8.6%-10.6% and CAG Diagnostics recurring revenue reported growth of 9.6%-11.6%, with projected 2026 organic revenue growth of 7.7%-9.7% and CAG Diagnostics recurring revenue organic growth of 8.7%-10.7%. FY26 consensus $4.68B.